Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsening Heart Failure

What is the purpose of this trial?

Primary Objectives:

  • Assess the safety and tolerability of sotagliflozin in hemodynamically stable patients hospitalized for worsening of heart failure.
  • Estimate the effects of sotagliflozin on plasma volume changes in hemodynamically stable patients hospitalized for worsening of heart failure.

Secondary Objectives:

  • Explore the effect of sotagliflozin on erythropoiesis, as assessed by changes in plasma erythropoietin levels, in hemodynamically stable patients hospitalized for worsening of heart failure, compared to placebo.
  • Explore the effect of sotagliflozin on changes in plasma NT-proBNP levels, in hemodynamically stable patients hospitalized for worsening of heart failure, compared to placebo.

Participation Guidelines

Ages: 18 years and older

Gender: Both


Sanofi-Aventis

Start Date: 12/04/2017

End Date: 07/31/2019

Last Updated: 02/22/2018

Study HIC#: 2000020192

Get Involved

For more information about this study, contact:
Jennifer Lynn Tainsh
jennifer.tainsh@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Jeffrey Moore Testani

Principal Investigator

Sub-Investigators